Areteia Therapeutics
Durham, United States· Est.
Areteia Therapeutics is developing dexpramipexole for the treatment of eosinophilic asthma.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $75M
About
Areteia Therapeutics is developing dexpramipexole for the treatment of eosinophilic asthma.
Respiratory
Funding History
1Total raised:$75M
Series A$75M